Primary hyperaldosteronism: the choice in favor of conservative surgery
-
Published:2023-12-12
Issue:11
Volume:101
Page:525-530
-
ISSN:2412-1339
-
Container-title:Clinical Medicine (Russian Journal)
-
language:
-
Short-container-title:jour
Author:
Annayev M. S.1ORCID, Stegniy K. V.1ORCID, Geltser B. I.1ORCID, Goncharuk R. A.1ORCID, Morozova A. M.1ORCID, Maslyantsev E. V.1ORCID
Affiliation:
1. Far Eastern Federal University
Abstract
Primary hyperaldosteronism (PHA) is the most common cause of secondary arterial hypertension among endocrine disorders. Given that patients with this pathology are at a higher risk of developing fatal and non-fatal cardiovascular events, early diagnosis and timely treatment are of great importance. Currently, the two main forms of PHA are aldosterone-producing adenoma and bilateral adrenal hyperplasia, which are treated with laparoscopic adrenalectomy or pharmacotherapy with mineralocorticoid receptor antagonists. Although most patients experience restoration of their functional and metabolic status after surgical intervention, some may develop postoperative adrenal insuffi ciency, which requires long-term hormone replacement therapy. This review examines the options for organ-preserving surgeries, such as partial adrenalectomy and selective embolization of the adrenal artery.
Publisher
Medical Informational Agency Publishers
Reference49 articles.
1. Beltsevich D.G., Troshina E.A., Melnichenko G.A., Platonova N.M., Ladygina D.O., Sheve A. Draft of the clinical practice guidelines “adrenal incidentaloma”. J. Endocrine Surgery. 2021;15(1):4–26. (In Russian)]. DOI: org/10.14341/serg12712 2. Chatzellis E., Kaltsas G. Adrenal Incidentalomas. 2019 Nov 7. In: Feingold K.R., Anawalt B., Blackman M.R., Boyce A., Chrousos G., Corpas E., de Herder W.W., Dhatariya K., Hofl and J., Dungan K., Hofl and J., Kalra S., Kaltsas G., Kapoor N., Koch C., Kopp P., Korbonits M., Kovacs C.S., Kuohung W., Laferrère B., Levy M., McGee E.A., McLachlan R., New M., Purnell J., Sahay R., Singer F., Sperling M.A., Stratakis C.A., Trence D.L., Wilson D.P., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. 3. Muradyan A.G., Kostin A.A., Vorobiov N.V., Tolkachev A.O. Metastatic adrenal tumors. Epidemiology, etiology, diagnosis. P.A. Herzen Journal of Oncology = Onkologiya. Zhurnal im. P.A. Gertsena. 2020;9(3):53–60. (In Russian). DOI: 10.17116/onkolog2020903153 4. Young W., Ladygina D.O., Balutina O.V., Beltsevich D.G. Primary aldosteronism: The Mayo clinic approach. Therapeutic Archive. 2020;92(10):83–87. (In Russian). DOI: 10.26442/00403660.2020.10.000754 5. Melnichenko G.A., Platonova N.M., Beltsevich D.G., Yukina I., Molashenko N.V., Troshina E.A. Primary hyperaldosteronism: diagnosis and treatment. A new look at the problem. According to the materials of the Russian Association of Endocrinologists clinical guidelines for primary hyperaldosteronism diagnosis and treatment. Consilium Medicum. 2017;19(4):75–85. (In Russian).
|
|